WO2016055696A1 - A method and a device for producing nanoparticles - Google Patents

A method and a device for producing nanoparticles Download PDF

Info

Publication number
WO2016055696A1
WO2016055696A1 PCT/FI2015/050664 FI2015050664W WO2016055696A1 WO 2016055696 A1 WO2016055696 A1 WO 2016055696A1 FI 2015050664 W FI2015050664 W FI 2015050664W WO 2016055696 A1 WO2016055696 A1 WO 2016055696A1
Authority
WO
WIPO (PCT)
Prior art keywords
pressure
nozzle
mixture
fluid
organic substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FI2015/050664
Other languages
English (en)
French (fr)
Inventor
Edward HÆGGSTRÖM
Jouko Yliruusi
Kai FALK
Heikki RÄIKKÖNEN
Jenni PESSI
Ilkka LASSILA
Antti Meriläinen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanoform Finland Oyj
Original Assignee
Nanoform Finland Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanoform Finland Oyj filed Critical Nanoform Finland Oyj
Priority to CA2961107A priority Critical patent/CA2961107C/en
Priority to FIEP15793857.2T priority patent/FI3204150T3/fi
Priority to ES15793857T priority patent/ES2969055T3/es
Priority to EP15793857.2A priority patent/EP3204150B1/en
Priority to DK15793857.2T priority patent/DK3204150T3/da
Priority to PL15793857.2T priority patent/PL3204150T3/pl
Priority to JP2017537021A priority patent/JP6599995B2/ja
Priority to US15/512,070 priority patent/US10098842B2/en
Publication of WO2016055696A1 publication Critical patent/WO2016055696A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/02—Crystallisation from solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • B01J2/04—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a gaseous medium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J3/00—Processes of utilising sub-atmospheric or super-atmospheric pressure to effect chemical or physical change of matter; Apparatus therefor
    • B01J3/008—Processes carried out under supercritical conditions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Optics & Photonics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Colloid Chemistry (AREA)
PCT/FI2015/050664 2014-10-06 2015-10-05 A method and a device for producing nanoparticles Ceased WO2016055696A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA2961107A CA2961107C (en) 2014-10-06 2015-10-05 A method and a device for producing nanoparticles
FIEP15793857.2T FI3204150T3 (fi) 2014-10-06 2015-10-05 Menetelmä nanopartikkeleiden tuottamiseksi
ES15793857T ES2969055T3 (es) 2014-10-06 2015-10-05 Un método para la producción de nanopartículas
EP15793857.2A EP3204150B1 (en) 2014-10-06 2015-10-05 A method for producing nanoparticles
DK15793857.2T DK3204150T3 (da) 2014-10-06 2015-10-05 Fremgangsmåde til at producere nanopartikler
PL15793857.2T PL3204150T3 (pl) 2014-10-06 2015-10-05 Sposób wytwarzania nanocząstek
JP2017537021A JP6599995B2 (ja) 2014-10-06 2015-10-05 ナノ粒子を製造するための方法及び装置
US15/512,070 US10098842B2 (en) 2014-10-06 2015-10-05 Method and a device for producing nanoparticles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20140266 2014-10-06
FI20140266A FI20140266A7 (fi) 2014-10-06 2014-10-06 Menetelmä ja laite nanopartikkeleiden valmistamiseksi

Publications (1)

Publication Number Publication Date
WO2016055696A1 true WO2016055696A1 (en) 2016-04-14

Family

ID=54540113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2015/050664 Ceased WO2016055696A1 (en) 2014-10-06 2015-10-05 A method and a device for producing nanoparticles

Country Status (10)

Country Link
US (1) US10098842B2 (enExample)
EP (1) EP3204150B1 (enExample)
JP (1) JP6599995B2 (enExample)
CA (1) CA2961107C (enExample)
DK (1) DK3204150T3 (enExample)
ES (1) ES2969055T3 (enExample)
FI (2) FI20140266A7 (enExample)
PL (1) PL3204150T3 (enExample)
PT (1) PT3204150T (enExample)
WO (1) WO2016055696A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105641968A (zh) * 2016-01-07 2016-06-08 中国原子能科学研究院 一种具有在线光谱监测功能的超临界流体络合反应装置
WO2018060547A1 (en) 2016-09-29 2018-04-05 Nanoform Finland Oy Device, method and kit for dissolution testing
WO2019094540A1 (en) * 2017-11-09 2019-05-16 Blh Ecology Concepts, Llc Process to produce nanoparticles
CN111215002A (zh) * 2020-01-20 2020-06-02 中南大学 高温高压超临界二氧化碳反应釜
WO2021084139A1 (en) 2020-03-23 2021-05-06 Bayer Aktiengesellschaft Nano-dry melting
WO2021152204A1 (en) * 2020-01-29 2021-08-05 Nanoform Finland Oyj System and method to produce particles of organic substances
WO2024153733A1 (en) 2023-01-18 2024-07-25 Helm Ag Crystalline nanoparticles comprising enzalutamide

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111012671B (zh) * 2019-11-25 2022-07-05 上海强德食品科技有限公司 一种微胶囊的物理制备方法
CN111721495B (zh) * 2020-06-16 2022-02-08 中国人民解放军国防科技大学 一种新型纳米粒子平面激光散射实验的粒子生成装置
AU2024210295A1 (en) 2023-01-18 2025-07-03 Nanoform Finland Oyj A method for crystallization of active pharmaceutical ingredients
WO2025125509A1 (en) 2023-12-12 2025-06-19 Targtex S.A. Chemotherapeutic agent and compositions
WO2025153768A1 (en) 2024-01-18 2025-07-24 Nanoform Finland Oyj Composition comprising crystalline nanosized apalutamide

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014407A1 (en) 1995-10-17 1997-04-24 Research Triangle Pharmaceuticals Insoluble drug delivery
WO1997031691A1 (en) 1996-03-01 1997-09-04 The University Of Kansas Methods and apparatus for particle precipitation and coating using near-critical and supercritical antisolvents
WO1998058722A1 (en) * 1997-06-20 1998-12-30 Smithkline Beecham Plc Treatment of a substance with a dense fluid (e.g. with a supercritical fluid)
WO1999065469A2 (en) 1998-06-19 1999-12-23 Rtp Pharma Inc. Processes to generate submicron particles of water-insoluble compounds
WO2006015358A2 (en) 2004-08-03 2006-02-09 Clemson University Aqueous suspension of nanoscale drug particles from supercritical fluid processing
US20060153921A1 (en) 2003-06-03 2006-07-13 Ferro Corporation Method for preparation of particles from solution-in-supercritical fluid or compressed gas emulsions
WO2007072072A2 (en) * 2005-12-20 2007-06-28 Accentus Plc Crystallisation apparatus and process with supercritical fluid
US7815426B2 (en) 2006-05-15 2010-10-19 Absize Inc. Apparatus for forming ultrafine particles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06102124B2 (ja) * 1985-12-27 1994-12-14 日本分光工業株式会社 超臨界流体による試料の分離回収方法
JP2774349B2 (ja) * 1990-03-17 1998-07-09 株式会社神戸製鋼所 微粒の製造方法
FR2802445B1 (fr) * 1999-12-15 2002-02-15 Separex Sa Procede et dispositif de captage de fines particules par piegeage au sein d'un melange solide de type neige carbonique
CN101918123B (zh) * 2007-12-07 2013-12-18 X喷雾微粒公司 生产微粒的方法与装置
JP5933234B2 (ja) * 2011-11-24 2016-06-08 国立大学法人東北大学 微粒子作製装置

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014407A1 (en) 1995-10-17 1997-04-24 Research Triangle Pharmaceuticals Insoluble drug delivery
WO1997031691A1 (en) 1996-03-01 1997-09-04 The University Of Kansas Methods and apparatus for particle precipitation and coating using near-critical and supercritical antisolvents
WO1998058722A1 (en) * 1997-06-20 1998-12-30 Smithkline Beecham Plc Treatment of a substance with a dense fluid (e.g. with a supercritical fluid)
WO1999065469A2 (en) 1998-06-19 1999-12-23 Rtp Pharma Inc. Processes to generate submicron particles of water-insoluble compounds
US20060153921A1 (en) 2003-06-03 2006-07-13 Ferro Corporation Method for preparation of particles from solution-in-supercritical fluid or compressed gas emulsions
WO2006015358A2 (en) 2004-08-03 2006-02-09 Clemson University Aqueous suspension of nanoscale drug particles from supercritical fluid processing
WO2007072072A2 (en) * 2005-12-20 2007-06-28 Accentus Plc Crystallisation apparatus and process with supercritical fluid
US7815426B2 (en) 2006-05-15 2010-10-19 Absize Inc. Apparatus for forming ultrafine particles

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JIRAPORN CHINGUNPITAK, SATIT PUTTIPIPATKHACHORN, YUICHI TOZUKA, KUNIKAZU MORIBE & KEIJI YAMAMOTO: "Micronization of Dihydroartemisinin by Rapid Expansion of Supercritical Solutions", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 34, no. 6, 2008, pages 609 - 617, XP002753256 *
MATSON D W ET AL: "PRODUCTION OF POWDERS AND FILMS BY THE RAPID EXPANSION OF SUPERCRITICAL SOLUTIONS", JOURNAL OF MATERIALS SCIENCE, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, vol. 22, no. 6, June 1987 (1987-06-01), pages 1919 - 1928, XP000537431, ISSN: 0022-2461, DOI: 10.1007/BF01132917 *
VRECER ET AL., INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 256, 2003, pages 3 - 15
ZHANG F X; WEI X L: "The influences of the structure of nozzle on coating effect in particle coating by Fluid-Rapid Expansion of Supercritical Solutions", ADVANCED MATERIALS RESEARCH - ENVIRONMENTAL ENGINEERING, vol. 864-867, 13 December 2013 (2013-12-13), pages 1204 - 1207, XP002753257 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105641968B (zh) * 2016-01-07 2018-04-17 中国原子能科学研究院 一种具有在线光谱监测功能的超临界流体络合反应装置
CN105641968A (zh) * 2016-01-07 2016-06-08 中国原子能科学研究院 一种具有在线光谱监测功能的超临界流体络合反应装置
JP7078610B2 (ja) 2016-09-29 2022-05-31 ナノフォーム フィンランド オサケユイチアユルキネン 溶出試験用の方法
WO2018060547A1 (en) 2016-09-29 2018-04-05 Nanoform Finland Oy Device, method and kit for dissolution testing
JP2019529921A (ja) * 2016-09-29 2019-10-17 ナノフォーム フィンランド オサケユイチア 溶出試験用の装置、方法及びキット
US11422121B2 (en) 2016-09-29 2022-08-23 Nanoform Finland Oyj Device, method and kit for dissolution testing
WO2019094540A1 (en) * 2017-11-09 2019-05-16 Blh Ecology Concepts, Llc Process to produce nanoparticles
CN111215002A (zh) * 2020-01-20 2020-06-02 中南大学 高温高压超临界二氧化碳反应釜
WO2021152204A1 (en) * 2020-01-29 2021-08-05 Nanoform Finland Oyj System and method to produce particles of organic substances
US11766650B2 (en) 2020-01-29 2023-09-26 Nanoform Finland Oyj System and method to produce particles of organic substances
EP3884930A1 (en) 2020-03-23 2021-09-29 Bayer AG Nano-dry-melting
WO2021084139A1 (en) 2020-03-23 2021-05-06 Bayer Aktiengesellschaft Nano-dry melting
WO2024153733A1 (en) 2023-01-18 2024-07-25 Helm Ag Crystalline nanoparticles comprising enzalutamide

Also Published As

Publication number Publication date
FI3204150T3 (fi) 2023-12-04
CA2961107C (en) 2023-01-03
CA2961107A1 (en) 2016-04-14
JP2017536983A (ja) 2017-12-14
DK3204150T3 (da) 2024-03-04
EP3204150A1 (en) 2017-08-16
US20170231914A1 (en) 2017-08-17
US10098842B2 (en) 2018-10-16
PT3204150T (pt) 2024-03-04
ES2969055T3 (es) 2024-05-16
FI20140266A7 (fi) 2016-04-07
JP6599995B2 (ja) 2019-10-30
PL3204150T3 (pl) 2024-05-13
EP3204150B1 (en) 2023-11-29

Similar Documents

Publication Publication Date Title
CA2961107C (en) A method and a device for producing nanoparticles
Loh et al. Overview of milling techniques for improving the solubility of poorly water-soluble drugs
Thakur et al. Formation of phenytoin nanoparticles using rapid expansion of supercritical solution with solid cosolvent (RESS-SC) process
Türk et al. Formation and stabilization of submicron particles via rapid expansion processes
Türk Manufacture of submicron drug particles with enhanced dissolution behaviour by rapid expansion processes
Zhang et al. Nanosuspension drug delivery system: preparation, characterization, postproduction processing, dosage form, and application
JP3986086B2 (ja) 近臨界および超臨界反溶媒を用いる粒子析出方法および被覆方法
Sievers et al. Micronization of water-soluble or alcohol-soluble pharmaceuticals and model compounds with a low-temperature Bubble Dryer®
Thakur et al. Rapid expansion of supercritical solution with solid cosolvent (RESS-SC) process: formation of 2-aminobenzoic acid nanoparticle
Tenorio et al. Controlled submicro particle formation of ampicillin by supercritical antisolvent precipitation
Duarte et al. Preparation of ethyl cellulose/methyl cellulose blends by supercritical antisolvent precipitation
US20160244547A1 (en) Efficient collection of nanoparticles
Cai et al. Supercritical fluid assisted atomization introduced by hydrodynamic cavitation mixer (SAA-HCM) for micronization of levofloxacin hydrochloride
Barrett et al. Increasing the dissolution rate of itraconazole processed by gas antisolvent techniques using polyethylene glycol as a carrier
Melzig et al. Formation of long-term stable amorphous ibuprofen nanoparticles via antisolvent melt precipitation (AMP)
Moribe et al. Micronization of phenylbutazone by rapid expansion of supercritical CO2 solution
Bakhbakhi et al. Precipitation of Ibuprofen Sodium using compressed carbon dioxide as antisolvent
Khapli et al. Supercritical CO2 based processing of amorphous fluoropolymer Teflon-AF: surfactant-free dispersions and superhydrophobic films
Al Harraq et al. Increasing aspect ratio of particles suppresses buckling in shells formed by drying suspensions
US20070116650A1 (en) Device, method and use for the formation of small particles
Satvati et al. Effects of extraction temperature, extraction pressure and nozzle diameter on micronization of cholesterol by RESS process
Akbari et al. Preparation and characterization of solid lipid nanoparticles through rapid expansion of supercritical solution
Sheth et al. Amorphous solid dispersion using supercritical fluid technology
Bakhbakhi et al. Supercritical antisolvent synthesis of fine griseofulvin particles
Gadermann et al. Formation of naproxen–polylactic acid nanoparticles from supercritical solutions and their characterization in the aerosol phase

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15793857

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2961107

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 15512070

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2017537021

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015793857

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015793857

Country of ref document: EP